SCHEMBL20620101

SCHEMBL20620101

O=C1CCCN(SI)c2cc(Cl)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOA P21397 3/20 0.36
MAOB P27338 3/20 0.36
LMNA P02545 2/20 0.36
NOTUM Q6P988 1/20 0.36
POLB P06746 1/20 0.36
VHL P40337 1/20 0.36
ELOC Q15369 1/20 0.36
ELOB Q15370 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
MAPK1 P28482 2/20 0.35
ALOX5 P09917 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23226222 0.79 KDM4E (0.43) ALDH1A1L3MBTL1LMNANOTUMKDM4E
SCHEMBL20619640 0.78 MEN1 (0.46) ALDH1A1L3MBTL1MAOAMAOBLMNA
SCHEMBL14746122 0.77 NOTUM (0.42) ALDH1A1TSHRALOX15L3MBTL1LMNA
SCHEMBL20614893 0.73 CHRM2 (0.33) ALDH1A1MAOAMAOBPOLBKDM4E
SCHEMBL20622390 0.73 ALDH1A1 (0.32) ALDH1A1LMNANOTUMPOLBKDM4E
SCHEMBL19557893 0.73 SRD5A1 (0.37) L3MBTL1MAOAMAOBS100A4
SCHEMBL20614936 0.71 CHRM2 (0.36) TSHRMAOAMAOBPOLB
SCHEMBL10914889 0.70 NOTUM (0.48) ALDH1A1L3MBTL1LMNANOTUMPOLB
SCHEMBL11161044 0.70 KMT2A (0.43) ALDH1A1LMNAMAPK1MEN1KMT2A
SCHEMBL3531672 0.68 MEN1 (0.43) ALDH1A1NOTUMKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
WO-2019006295-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 ALDH1A1 721/4885TSHR 4169/4885ALOX15 1325/4885
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 ALDH1A1 721/4885TSHR 4169/4885ALOX15 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.